Hanger, Inc. provides orthotic and prosthetic (O&P) services; and distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to patients and businesses in acute, post-acute, and clinic settings in the United States. It operates through two segments, Patient Care and Products & Services. The Patient Care segment owns and operates Hanger clinic, which specializes in the design, fabrication, and delivery of custom O&P devices through patient care clinics and satellite locations; and provides payor network contracting services to other O&P providers. The Products & Services segment procures and distributes O&P parts, componentry, and devices to independent O&P providers; and develops specialized rehabilitation technologies and provides evidence-based clinical programs for post-acute rehabilitation to patients at approximately 4,000 skilled nursing and post-acute providers. This segment also manufactures and sells therapeutic footwear for diabetic patients in the podiatric market. As of December 31, 2019, the company operated approximately 701 patient care clinics, and 111 satellite locations in 46 states and the District of Columbia. The company was formerly known as Hanger Orthopedic Group, Inc. and changed its name to Hanger, Inc. in June 2012. Hanger, Inc. was founded in 1861 and is headquartered in Austin, Texas.
HNGR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for HNGR, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Hanger Inc ranked in the 83th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for HNGR, they are:
The stock's equity weight, or the proportion of capital from equity relative to debt, is 57. Notably, its equity weight is greater than only 14.3% of US equities in the Healthcare sector yielding a positive free cash flow.
The company's compound free cash flow growth rate over the past 2.79 years comes in at 0.42%; that's greater than 76.48% of US stocks we're applying DCF forecasting to.
Hanger Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as HNGR, try ASNB, AMRX, HCA, VMD, and MODV.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Hanger, Inc. New York, January 14, 2021 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Hanger, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review discussion held on 11 January 2021 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, announced today that members of its management team will participate in presentations and meetings with institutional investors at the 39th Annual J.P. Morgan Healthcare Conference taking place Jan. 11-14, 2021.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.